Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.
Where this comes from
- Record sourced from PubMed, PMID 40177856.
- Also identified by DOI 10.1002/oby.24262 and PMC identifier 12015648.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Obesity management requires personalized approaches. Using data from the Aviitam platform in France, this study aimed to do the following: 1) explore psychological and behavioral patterns through clustering techniques; 2) validate the robustness of these clusters; and 3) assess their association with weight-loss outcomes in severe obesity under semaglutide treatment. Phase 1 included 989 adults with BMI ≥ 25 kg/m<sup>2</sup> who completed validated questionnaires, including the Hospital Anxiety and Depression Scale (HADS) and Intuitive Eating Scale-2 (IES-2). Phase 2 validated robustness in 492 individuals. Phase 3 applied clusters to 125 individuals with BMI ≥ 40 kg/m<sup>2</sup> who were treated with semaglutide 2.4 mg/week at Montpellier University Hospital, assessing weight-loss trajectories over 12 months. The following two clusters were identified: the Intuitive Eaters Group (IEG, n = 482); and the Emotionally Driven Eaters Group (EDEG, n = 507). The IEG exhibited lower emotional distress and higher intuitive eating scores. HADS and IES-2 distinguished clusters effectively (area under the curve, 0.95). Robustness was confirmed in Phase 2. In Phase 3, the IEG demonstrated a significantly more favorable weight-loss trajectory compared to the EDEG (p = 0.03). Psychological and behavioral clusters identified through HADS and IES-2 are associated with weight loss under semaglutide treatment, suggesting the value of integrating psychological and behavioral profiling into obesity care.
Medical subject headings
- Weight Loss
- Glucagon-Like Peptides
- Mental Health
- Feeding Behavior
- Obesity, Morbid
- Obesity
- Anti-Obesity Agents